Skip to content


Department of Medicine

Message from the Chief

C. Ola Landgren, M.D., Ph.D.Welcome to the Division of Myeloma, part of the Miller School’s Department of Medicine. 

Myeloma, also called multiple myeloma, is a cancer of plasma cells, which are a type of white blood cell that produces antibodies to protect against infection. When myeloma takes hold, cancer cells grow out of control, crowding out healthy blood cells and producing abnormal proteins.

Over the past few years, the Miller School of Medicine has assembled a team of myeloma experts from institutions around the world that are leading research on multiple myeloma treatments.

Our team consistently publishes consequential studies and influences opinions on how to manage the disease, focusing on topics such as myeloma precursor disease, including smoldering myeloma. Our mission includes training the next generation of thought leaders, who will build on and push our research to the next level.

Our faculty has also developed the Advanced Myeloma Fellowship, a one-year offering that exposes fellows to patient care and provides in-depth research opportunities at the only dedicated multiple myeloma program in South Florida.

Group photo of the Myeloma Faculty

We use a team-based, individualized approach for patient care, considering the features of each person’s disease to tailor treatment and early intervention strategies. 

We have a broad portfolio of state-of-the-art clinical trials across different stages of the disease. For multiple myeloma, our trials offer approaches that may improve on standard options, choices to those who have none, and better diagnostics to optimize a patient’s treatment strategy. 

For people with early signs of abnormal plasma cells, we offer trials examining early intervention and advanced characterization and tracking, so that we may understand an individual’s risk of developing multiple myeloma in the future.

Our dedicated Myeloma Research Institute will accelerate the speed of the Miller School’s research in discovery science, drug development, and translational investigation, and will serve as a training ground for future specialists and leaders in the field of multiple myeloma.

Thank you for your interest in our division.

- C. Ola Landgren, M.D., Ph.D.